Building Pharmaceutical Outsourcing Partnerships

Immunomedics’s chemistry, which involves a maleimide group on one end of the linker, allows for attaching up to eight drug molecules per antibody site-specifically at reduced interchain disulfides while avoiding the formation of dimers and aggregates. The pH-sensitive, cleavable linkage is moderately stable, with the potential to release SN-38 in the acidic tumor microenvironment and increase the drug’s bioavailability. Together, these features allow for reduced toxicity, higher antibody doses, repeated therapy cycles, and a better therapeutic window, Immunomedics says.

Source :

Building pharmaceutical outsourcing partnerships
The Pharma Industry -- Transactional Outsourcing and Strategic Partnerships: An Insider's Perspective
Strategic Outsourcing — The Road to Cost Efficiencies and Increased Productivity in Clinical Development
Pharma And Biotechs Offer Rewards And Risk - Which Will You Choose?
Healthcare Disruption: Pharma 3.0 Will Drive Shift from Life Science to HealthTech Investing (Part I of III)
Emerging business models for pharma
Four steps to building an innovation culture in pharma
TAKE Solutions partners with UBM for India Pharma Awards 2015
Letco Med, L.L.C. Announces Partnership with ARL Bio Pharma to Launch Quality Savings Program for Compounding Pharmacists
Three stories of pharmaceutical outsourcing